Interstitial Cystitis Market
Interstitial Cystitis (IC), also known as Bladder Pain Syndrome (BPS) is a chronic syndrome that results in recurring fits of pain and pressure in the bladder and pelvic.
Interstitial Cystitis / bladder pain syndrome pose quite a high treatment burden for patients in terms of both cost and duration. A definite diagnosis of IC/ BPS is still tricky, and the indication remains highly misdiagnosed, especially in men. Often, misdiagnosis leads to the initiation of the treatment regimen of other indications, which eventually adds to the overall cost burden faced by patients.
However, the Interstitial Cystitis market comprises a robust pipeline therapies in late and mid-stage development, which are expected to be launched shortly and provide a better treatment option for people affected with it.
Some of the key pharma companies in the Interstitial cystitis market includes KYORIN Pharmaceutical Co., Ltd., UCB, Lipella Pharmaceuticals Inc., Grünenthal Group, Astellas Pharma US, Seikagaku Corporation and many others.
For more details visit:
https://www.delveinsight.com/blog/interstitial-cystitis-market/
Gastroparesis Market
The total gastroparesis prevalent population in the 7MM was 34,057,658 in 2019. Among the major types of Gastroparesis, i.e., idiopathic, diabetic, and post surgical Gastroparesis, Idiopathic Gastroparesis accounted for a higher number of gastroparesis cases.
In 2019, there were approximately 14,665,140 cases of idiopathic Gastroparesis, and 8,621,552 cases for diabetic Gastroparesis in the 7MM.
The Gastroparesis market size in the 7MM was found to be USD 3,170.01 million in 2019, as per Delveinsight analysis, the market size of Gastroparesis is expected to change during the forecast period.
Some of the key Pharmaceutical companies in the Gastroparesis market include Allergan, Evoke Pharma, Vanda Pharmaceuticals, Takeda, CinRx Pharma, and many others.
For more details visit:
https://www.delveinsight.com/blog/gastroparesis-market-landscape/
Most Common Infectious Diseases in the World
Infectious Diseases are one of the leading causes of deaths worldwide. As per the WHO, “Infectious diseases kill over 17 million people a year”.
The emergence of new infectious diseases such as Ebola Infection, Zika Infection, and many others have caused severe social and economic crises in the world. The most recent and ongoing viral infection, COVID-19, has wreaked havoc on the human race. Not only has it resulted in a loss of life, but also the World economy toppling down.
Some of the leading infectious diseases that have a constant impact on human health at the global level in terms of number of deaths and cases includes-Tuberculosis, Malaria, Pneumonia, Diarrhoea, Viral Hepatitis, HIV/ AIDS and others.
For more detailed information on Infectious Diseases, visit: https://www.delveinsight.com/blog/infectious-diseases/
Celiac Disease Market
As per DelveInsight, there were 687,959 Celiac Disease diagnosed cases in 2019 in the United States. The Celiac Disease current market size (2020) in the United States is USD 833 Million.
Among the EU5 countries, Italy is the leading country that has the highest diagnosed cases nowadays, the diagnostic rate of Celiac Disease in Italy is much higher than in the past, mainly due to the case-finding policy adopted by doctors and greater disease awareness. There were 226,843 diagnosed cases in Italy in the year 2019 and the number is expected to show a high jump in the coming 10 years.
Some of the key pharma companies involved in the therapeutic market of Celiac disease and are expected to make a significant contribution in driving the Celiac disease market in the upcoming years includes 9 Meters Biopharma, Inc. BIOPHARMA, ImmunogenX, Provention Bio, Cour Pharmaceuticals Development Company, Takeda, Precigen ActoBio, Dr. Falk Pharma GmbH, and ZEDIRA GmbH.
For more details on Celiac Disease market and the promising drugs in the pipeline, visit:
https://www.delveinsight.com/blog/celiac-disease-market-key-companies/
Gastroparesis Market
The total diagnosed prevalent population of Gastroparesis in the 7MM was 15,633,997 in 2019. The Idiopathic Gastroparesis accounted for around 14,665,140 cases while the Diabetic Gastroparesis accounted for about 8,621,552 cases among the seven major markets. A higher prevalence of Gastroparesis in females as compared to males was observed in 7MM in 2019.
The market size of Gastroparesis in the 7MM was USD 3,170.01 Million in 2019, according to DelveInsight, Gastroparesis Market in the 7MM is expected to change in the study period.
Some of the key companies in the Gastroparesis Market include Allergan, Censa Pharmaceuticals, Evoke Pharma, Bird Rock Bio, Vanda Pharmaceuticals, CinDome Pharma, Theravance Biopharma, Takeda and many others.
For more details on Gastroparesis market visit: https://www.delveinsight.com/report-store/gastroparesis-market
Hereditary Transthyretin Amyloidosis (hATTR) Competitive Landscape and Market Insights
In 2017 the Familial Amyloid Polyneuropathy (FAP) patient in the United States was found to be 2,588 while Italy and France had 612 and 512 FAP patients respectively.
With a growth rate of 10.2% Hereditary Transthyretin Amyloidosis (hATTR) has the highest diagnosed prevalence in the United States while Japan has the lowest number which is expected to grow at a CAGR of 9.9% over the forecast period.
The market size of Hereditary Transthyretin Amyloidosis (hATTR) in the 7MM was USD 306.9 Million in 2017.
The key players in the Hereditary Transthyretin Amyloidosis (hATTR) market includes Alnylam Pharmaceuticals, Eidos Therapeutics, Ionis Pharmaceuticals and many others.
For more details on hrrt market visit: https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market
Cannabis, popularly known as Marijuana, is the most commonly used illicit drug after alcohol. More than 150 Million people regularly smoke marijuana. Approximately 11.8 Million young adult American populations consumed marijuana in 2017 estimated the results of a survey by the National Survey on Drug Use and Health.
Cannabis is widely used to alleviate pain such as neuropathic pain, fibromyalgia, rheumatoid arthritis, and mixed chronic pain.
Several pharmaceutical companies are involved in exploring the potential that the medical marijuna market offers. Companies including MedReleaf, Tetra Bio-Pharma, TO Pharmaceuticals, Corbus Pharmaceuticals, Therapix Biosciences, Arena Pharmaceuticals, Canbex Therapeutics, Daisy Pharma Opioid Venture, Tilray, One World Cannabis Ltd, One World Cannabis Ltd., Centrexion Therapeutics and several others are proactively testing different strains of marijuana for different indications.
An influx of companies, the launch of pipeline therapies, and the legalization of marijuana/ cannabis are the major drivers of the medical marijuana market.
For more detailed information on Marijuana Market Size and Growth, visit: https://www.delveinsight.com/blog/medical-marijuana-market/
Vasomotor Symptoms Market
The total prevalent population of Vasomotor Symptoms associated with post menopause in 7MM was 41,096,968 in 2017. The prevalent population of Hot Flashes associated with Post Menopause in the United States was found to be 18, 926,632 in 2017, while japan registered 4,553,108 prevalent cases of Hot Flashes.
The market size of Hot Flashes associated with Post-Menopause in the 7MM was USD 1,755.8 Million in 2017.
Increasing awareness, rising emerging therapies are the key factors expected to drive the Vasomotor symptoms (Hot flashes/Night sweats) Market forward in the coming years.
The key players in the Vasomotor symptoms (Hot flashes/Night sweats) Market includes KaNDy Therapeutics, Fervent Pharmaceuticals, Astellas Pharma, Mithra Pharmaceuticals, Sojournix, Mitsubishi Tanabe Pharma and many others.
For more details on visit: https://www.delveinsight.com/report-store/vasomotor-symptoms-market
Celiac Disease Market
The total prevalent population of Celiac Disease in the 7MM was 6,334,993 in 2017. The total prevalent population of Celiac Disease in Germany was found to be 738,357 in 2017, while the UK and Spain have 650,676 and 421,326 prevalent cases respectively.
The market size of Celiac Disease in the 7MM was found to be USD 1,242.8 Million in 2017, according to DelveInsight, Celiac Disease market in the 7MM is expected to change in the study period 2017–2030.
The key players in the Celiac Disease market includes 9 Meters Biopharma, Takeda, Cour Pharmaceuticals, ImmunogenX, Precigen , Provention Bio, Dr Falk Pharma, ZEDIRA GmbH and many others.
For more details on Celiac Disease market, visit: https://www.delveinsight.com/report-store/celiac-disease-cd-market
Non-Cystic Fibrosis Bronchiectasis (NCFB) Market
The prevalence of Non-cystic Fibrosis Bronchiectasis in the 7MM was 772,285 in 2017. The prevalence of NCFB in the United States was found to be 443,632 in 2017, while Germany has around 45,560 prevalent cases.
The market size of Non-cystic Fibrosis Bronchiectasis in the 7MM was found to be USD 1,211 Million in 2017, according to DelveInsight, NCFB market in the 7MM is expected to change in the study period 2017–2030.
The key pharma players in the Non-cystic Fibrosis Bronchiectasis market include Aradigm , Zambon, Insmed, Novartis and many others.
For more details on Non-Cystic Fibrosis Bronchiectasis (NCFB) Market visit:
https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-market
Hereditary Transthyretin Amyloidosis (hATTR) Market size
Hereditary ATTR (hATTR) amyloidosis is the most common form of ATTR and also a very rare disease. Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis cardiomyopathy (FAC) are the two common types of hATTR.
The Hereditary Transthyretin Amyloidosis (hATTR) Market size in the 7MM was estimated to be USD 306.9 Million in 2017 and is anticipated to grow further in the forecast period 2020-30 owing to recent approvals and pipeline therapies. Among the 7MM geographies, the United States accounted for the 54% share of the total hATTR market size.
The key pharma companies in the Hereditary transthyretin amyloidosis market includes Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and many others.
For more details on Hereditary Transthyretin Amyloidosis (hATTR) Market, visit: https://www.delveinsight.com/blog/hattr-market-hereditary-transthyretin-amyloidosis-market/
Dup15q Syndrome Market
The total prevalent cases of Dup15q Syndrome in the 7MM was found to be 45,884 in 2017. The prevalence of Dup15q syndrome in the United States was 22,077 in 2017.
The market size of Dup15q syndrome in the 7MM was USD 15.69 Million in 2017, according to DelveInsight, Dup15q syndrome market in the 7MM is expected to change in the study period 2017–2030.
Most of the patients suffering from the Dup15q syndrome show a variety of symptoms, and the current treatment approach helps in managing them. The choice of treatment to be adopted depends on the type of symptoms the person is showing. Some of the key players in the therapeutic development of Dup15q syndrome include Ovid Therapeutics, Takeda and others.
For more details on Dup15q syndrome market, visit: https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast
Angelman Syndrome Market
The total prevalent cases of Angelman Syndrome in the seven major markets was 57,716 in 2017. Among the 7MM, the prevalence of Angelman Syndrome in the United States and Germany were found to be 21,715 and 6,448 respectively in 2017.
The therapeutic market of Angelman Syndrome in the 7MM was USD 255 Million in 2017, which is expected to increase during the forecast period 2017-2030.
The key players in the Angelman Syndrome market include Ovid Therapeutics, GeneTx Biotherapeutics, PTC Therapeutics and many others.
For more details on Angelman Syndrome Market visit: https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
Signs And Symptoms Of ADHD
ADHD is one of the most commonly diagnosed mental disorders in children, it is neither preventable nor cured. ADHD is often referred to as Attention Deficit Disorder.
It is observed that boys are most affected with ADHD as compared to girls. As per the NCBI, ADHD affects up to 1 in 20 children in the USA. Among the seven major markets the US accounted for about 28% of the total ADHD prevalent cases in 2017.
Difficulty in keeping their attention and concentration on tasks, forget or lose necessary things, difficulty in organising an activity, distraction by noise and unrelated thoughts, loseing track of daily activities are some of the key Inattentive symptoms of ADHD in childrens.
Similarly, fidgeting and squirming, talking excessively, Impulsive decision making, constant physical movement and touching objects are some of the key Hyperactivity and impulsivity symptoms of ADHD.
Several pharma players at the global level such as Aevi Genomic Medicine, Amarantus BioScience, NLS Pharma, Supernus Pharmaceuticals, Genentech, Otsuka Pharmaceutical, and RespireRx Pharmaceuticals are involved in the therapeutic development of ADHD.
For more details visit: https://www.delveinsight.com/blog/signs-and-symptoms-of-adhd/
Cancer cachexia market
More than half of the cancer patients suffer from Cachexia, and over 30% of the cancer patients succumb to death due to complications that arise from cachexia.
However, advanced medical technologies and emerging therapies have led to an increase in the diagnosis and treatment of cancer cachexia.
Several pharma companies including Tetra Bio-Pharma ,Helsinn Group/Ono Pharmaceutical, AEterna Zentaris Inc., ACTIMED THERAPEUTICS, PsiOxus Therapeutics, Pfizer, XBiotech USA, Inc., Cannabics Pharmaceuticals Inc., NGM Biopharmaceuticals, Artelo Biosciences, Inc. and many more are advancing cancer cachexia pipeline to address the unmet needs in the Cancer cachexia market.
Visit to read more: https://www.delveinsight.com/blog/cancer-cachexia-pipeline-therapies/
Dementia With Diabetes Market
The total prevalent cases of Dementia in 7MM was 21,021,021 in 2017. Among the seven major markets, the EU5 countries accounted for about 32.42% of the patient pool in 2017.
The market size of Dementia with Diabetes in 2017 was USD 1,180.98 Million in 7MM, which is expected to increase during the study period 2017-2030.
Some of the key players in the Dementia with Diabetes Market includes VTV Therapeutics, Novo Nordisk and others.
For more details on Dementia with Diabetes Market, visit: https://www.delveinsight.com/report-store/dementia-with-diabetes-market-forecast
Uveitis Market
In 2017, the total prevalent cases of Uveitis in the United States were 357,791. It was found that in the United States, Acute Anterior Uveitis accounted for 43% of the total cases of Uveitis in 2017.
The market size of Uveitis in the seven major markets (i.e the US, Germany, France, Italy, the UK, Spain and Japan) was found to be USD 1,045.9 Million in 2017, which is expected to increase during the forecast period.
The key players in the Uveitis market includes Aldeyra Therapeutics, Santen Pharmaceutical, Oculis, EyeGate Pharma, Novartis, Clearside Biomedical, Bristol-Myers Squibb, Sanofi, Eyevensys and many others.
For more details visit: https://www.delveinsight.com/report-store/uveitis-market
Adrenoleukodystrophy Market
As per DelveInsight’s epidemiological analysis, Adrenoleukodystrophy prevalence in the 7MM (the US, EU5 (the UK, Germany, France, Italy and Spain) and Japan) was estimated to be 55,242 in 2017.
DelveInsight reckons an increase in the global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 million in the 7MM in 2017.
Some of the Key pharma players involved in the development of therapies to address the unmet needs prevailing in the Adrenoleukodystrophy market include Bluebird Bio, Minoryx Therapeutics, Medday Pharmaceuticals, Magenta Therapeutics, and others.
For more details visit: https://www.delveinsight.com/blog/adrenoleukodystrophy-market-size/
Essential Thrombocythemia Market
The total prevalent population of Essential Thrombocythemia (ET) in 2017 was 232,688 in the seven major markets.
With 142,635 cases in 2017, the United States registered the highest prevalent population of Essential Thrombocythemia among the 7MM. Out of all the cases in the United States (in 2017), it is being observed that the age-group of 60-80 years accounted for the highest cases of Essential Thrombocythemia.
The market size of Essential Thrombocythemia (ET) was found to be USD 616.05 Million in 2017, which is expected to increase during the forecast period 2017-2030.
The key players in the Essential Thrombocythemia Market includes PharmaEssentia, Eli Lilly and Company, Novartis, Geron Corporation, Italfarmaco, Imago BioSciences, Galena Pharma, and many others.
For more details visit: https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights
Covid-19 Vaccine Candidate In India
India registered its first COVID19 case on 30-January-2020, since then the cases are on continuous rise. On 29-July-2020 the tally of total cases has crossed the figure of 1.50 Million with more than 30 thousand casualties.
Several pharma and biotech companies are developing and manufacturing safe and effective vaccines to fight coronavirus. In The Global race for the COVID-19 (CoronaVirus) vaccine, India Stands as a strong player.
Currently, India has more than 25 companies invested in the COVID 19 (Novel Coronavirus 19 ) vaccine development.
Some of the Indian companies with their vaccine in the different testing and clinical phases includes Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Zydus Group, Mynvax Private Limited, Biological E. Limited, Indian Immunologicals Limited, Panacea Biotec and others.
For more details on Covid-19 vaccine candidate in india, visit: https://www.delveinsight.com/blog/covid-19-vaccine-in-india/
Joined Feb 2020
